<DOC>
	<DOCNO>NCT00141089</DOCNO>
	<brief_summary>Tegaserod ( HTF919 ) aminoguanidine indole compound member class subgroup-selective 5-hydroxytryptamine ( 5-HT ) agonist . The aim study evaluate efficacy safety tegaserod bowel habit male patient chronic constipation .</brief_summary>
	<brief_title>Assessment Efficacy Safety Tegaserod Male Patients With Chronic Constipation .</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>A 6month history constipation define &lt; 3 complete spontaneous bowel movement per week &gt; 1 follow symptom &gt; 25 % time : hard stool , sensation incomplete evacuation strain Patients cancer , inflammatory bowel disease structural bowel disease Past current diagnosis irritable bowel syndrome exclude . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Male patient , chronic constipation , tegaserod</keyword>
</DOC>